<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2015-10-27" updated="2019-12-02">
  <drugbank-id primary="true">DB09266</drugbank-id>
  <name>Technetium Tc-99m tilmanocept</name>
  <description>Technetium Tc-99m tilmanocept is a radiopharmaceutical diagnostic imaging agent approved by the U.S. Food and Drug Administration (FDA) for the imaging of lymph nodes with or without scintigraphic imaging. It is a macromolecule consisting of multiple units of diethylenetriaminepentaacetic acid (DTPA) and mannose, each covalently attached to a 10 kDa dextran backbone [FDA Label]. DTPA serves as a chelating agent for technetium Tc 99m to bind [FDA Label]. Technetium Tc-99m tilmanocept is used in lymphatic mapping and lymph node localization in breast cancer, melanoma, clinically node-negative squamous cell carcinoma of the oral cavity, and other solid tumors [A32169, A32170]. Detecting sentinel lymph node (SLN) is clinically useful in the prognosis and management of the disease, as it is considered as the first lymph node that receives afferent lymphatic drainage from a primary tumor, and may be used to predict tumour staging and metastasis [A32170]. However, as nodal micrometastasis in breast cancer may not be associated with significant changes in survival, it is also important to identify clinically node-negative patients [A32170]. &#13;
&#13;
Technetium Tc-99m tilmanocept is a novel CD206 receptor-targeted molecule that selectively binds to mannose receptors expressed on the surface of reticuloendothelial cells in lymph nodes [A32168]. Due to its relatively small molecular weight and small molecular diameter of 7 nm [A32168], technetium Tc-99m tilmanocept displays more rapid injection site clearance, high sentinel node extraction, and low distal node accumulation compared to other conventional radiocolloids [A32170]. It achieves high overall accuracy in detecting SLN [A32169]. Once reconstituted and labelled, technetium Tc99m tilmanocept is intended to be injected in close proximity to the tumor being diagnosed and employed in preoperative gamma detection imaging in combination with various other techniques, including scintigraphy, SPECT, and SPECT/CT [L1157]. It may be administered via subcutaneous, intradermal, subareolar, or peritumoral injection, depending on the tutor location and planned injection technique [FDA Label]. It is marketed under the trade name Lymphoseek. Potential application of technetium Tc-99m tilmanocept to other cancers are being investigated [A32170].</description>
  <cas-number>1262984-82-6</cas-number>
  <unii>8IHI69PQTC</unii>
  <state>solid</state>
  <groups>
    <group>approved</group>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A32168</ref-id>
        <pubmed-id>23504141</pubmed-id>
        <citation>Wallace AM, Han LK, Povoski SP, Deck K, Schneebaum S, Hall NC, Hoh CK, Limmer KK, Krontiras H, Frazier TG, Cox C, Avisar E, Faries M, King DW, Christman L, Vera DR: Comparative evaluation of [(99m)tc]tilmanocept for sentinel lymph node mapping in breast cancer patients: results of two phase 3 trials. Ann Surg Oncol. 2013 Aug;20(8):2590-9. doi: 10.1245/s10434-013-2887-8. Epub 2013  Mar 17.</citation>
      </article>
      <article>
        <ref-id>A32169</ref-id>
        <pubmed-id>25670018</pubmed-id>
        <citation>Agrawal A, Civantos FJ, Brumund KT, Chepeha DB, Hall NC, Carroll WR, Smith RB, Zitsch RP, Lee WT, Shnayder Y, Cognetti DM, Pitman KT, King DW, Christman LA, Lai SY: [(99m)Tc]Tilmanocept Accurately Detects Sentinel Lymph Nodes and Predicts Node Pathology Status in Patients with Oral Squamous Cell Carcinoma of the Head and Neck: Results of a Phase III Multi-institutional Trial. Ann Surg Oncol. 2015 Oct;22(11):3708-15. doi: 10.1245/s10434-015-4382-x. Epub 2015 Feb 11.</citation>
      </article>
      <article>
        <ref-id>A32170</ref-id>
        <pubmed-id>25956693</pubmed-id>
        <citation>Surasi DS, O'Malley J, Bhambhvani P: 99mTc-Tilmanocept: A Novel Molecular Agent for Lymphatic Mapping and Sentinel Lymph Node Localization. J Nucl Med Technol. 2015 Jun;43(2):87-91. doi: 10.2967/jnmt.115.155960. Epub 2015 May 8.</citation>
      </article>
    </articles>
    <textbooks/>
    <links>
      <link>
        <ref-id>L1157</ref-id>
        <title>Electronic Medicines Compendium: Lymphoseek (technetium TC 99M tilmanocept) Monograph</title>
        <url>https://www.medicines.org.uk/emc/product/2572/smpc</url>
      </link>
    </links>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication>Indicated with or without scintigraphic imaging for lymphatic mapping using a handheld gamma counter to locate lymph nodes draining a primary tumor site in patients with solid tumors for which this procedure is a component of intraoperative management [FDA Label].&#13;
&#13;
Indicated with or without scintigraphic imaging for guiding sentinel lymph node biopsy using a handheld gamma counter in patients with clinically node negative squamous cell carcinoma of the oral cavity, breast cancer or melanoma [FDA Label]. </indication>
  <pharmacodynamics>Technetium Tc 99m tilmanocept binds to the CD206 receptors on the surface of reticuloendothelial cells, such as macrophages and dendritic cells, which are highly expressed in lymph nodes. In clinical studies, technetium Tc 99m tilmanocept has been shown to be detectable in lymph nodes within 10 minutes and up to 30 hours after injection [FDA Label]. Moreover, Phase 1 clinical studies showed approximately 0.5 to 1.8% of a dose accumulating in draining lymph nodes via specific binding after about 30 minutes. Technetium Tc99m tilmanocept bindng appears to be independent of tumor type or severity [L1157]. It displays rapid injection site clearance, rapid accumulation, long retention in the sentinel node, and low distal node accumulation [A32170].</pharmacodynamics>
  <mechanism-of-action>The mannose of the molecule acts as a ligand and guides the molecule to selectively bind to human mannose binding receptors (CD206) located on the surface of reticuloendothelial cells residing within lymph nodes, such as macrophages and dendritic cells [FDA Label]. According to _in vitro_ studies, technetium Tc 99m tilmanocept demonstrates selective binding to CD206 with a primary binding site affinity of Kd = 2.76 x 10^-11 M. </mechanism-of-action>
  <toxicity>Tilmanocept was not mutagenic _in vitro_ in the Ames bacterial mutation assay and in the _in vitro_ mouse lymphoma test, and was negative in the _in vivo_ micronucleus test in mice. Studies assessing the carcinogenic potential or effects on reproductive fertility have not been conducted [FDA Label]. </toxicity>
  <metabolism>Although the metabolism of technetium Tc 99m tilmanocept has not yet been experimentally investigated, tilmanocept may be metabolized in the liver to its main component molecules dextran, mannose and diethylenetriaminepentaacetic acid (DTPA). Subsequently, dextran may be further broken down into glucose. Furthermore, given the predominant role of the liver in the metabolism of technetium Tc 99m tilmanocept, some biliary elimination of the radiopharmaceutical is also expected. [L1557]</metabolism>
  <absorption>In clinical studies, technetium Tc 99m tilmanocept was detectable in lymph nodes within 10 minutes and up to 30 hours after injection. The maximum amount of the accumulated radioactive dose in the liver, kidney, and bladder was reached at 1 hour post-injection and was approximately 1-2% of the total, injected dose in each tissue [FDA Label].</absorption>
  <half-life>Technetium Tc99m tilmanocept decays by isomeric transition with a physical half-life of approximately 6 hours. The half-life at the injection site of 1.8 to 3.1 hours [FDA Label].</half-life>
  <protein-binding/>
  <route-of-elimination>It is believed that technetium Tc 99m tilmanocept is eliminated primarily through the kidneys as primary metabolites. Technetium Tc 99m tilmanocept may undergo hepatic elimination and biliary elimination [L1557]</route-of-elimination>
  <volume-of-distribution/>
  <clearance>In dose-ranging clinical studies, injection site clearance rates were similar across doses ranging from 4 to 200 mcg with a mean elimination rate constant in the range of 0.222 to 0.396/hr [FDA Label].</clearance>
  <salts/>
  <synonyms>
    <synonym language="english" coder="">Technetium (99mTc) tilmanocept</synonym>
    <synonym language="english" coder="">Technetium Tc 99m Tilmanocept</synonym>
    <synonym language="english" coder="">Technetium Tc99 tilmanocept</synonym>
  </synonyms>
  <products>
    <product>
      <name>Kit for the preparation of Lymphoseek (technetium Tc 99m tilmanocept)</name>
      <labeller>Cardinal Health 414, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>65857-425</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-09-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength>250 ug/1</strength>
      <route>Intradermal; Subcutaneous</route>
      <fda-application-number>NDA202207</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Kit for the preparation of Lymphoseek (technetium Tc 99m tilmanocept)</name>
      <labeller>Cardinal Health 414, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>65857-450</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-09-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength>250 ug/1</strength>
      <route>Intradermal; Subcutaneous</route>
      <fda-application-number>NDA202207</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Kit for the preparation of Lymphoseek (technetium Tc 99m tilmanocept)</name>
      <labeller>Navidea Biopharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>52579-1600</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-03-13</started-marketing-on>
      <ended-marketing-on>2019-06-01</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength>250 ug/1</strength>
      <route>Intradermal; Subcutaneous</route>
      <fda-application-number>NDA202207</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Kit for the preparation of Lymphoseek (technetium Tc 99m tilmanocept)</name>
      <labeller>Navidea Biopharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>52579-1604</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-10-20</started-marketing-on>
      <ended-marketing-on>2019-06-01</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength>250 ug/1</strength>
      <route>Intradermal; Subcutaneous</route>
      <fda-application-number>NDA202207</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>Kit for the preparation of Lymphoseek (technetium Tc 99m tilmanocept)</name>
      <ingredients>Technetium Tc-99m tilmanocept</ingredients>
    </mixture>
    <mixture>
      <name>Kit for the preparation of Lymphoseek (technetium Tc 99m tilmanocept)</name>
      <ingredients>Technetium Tc-99m tilmanocept</ingredients>
    </mixture>
    <mixture>
      <name>Kit for the preparation of Lymphoseek (technetium Tc 99m tilmanocept)</name>
      <ingredients>Technetium Tc-99m tilmanocept</ingredients>
    </mixture>
    <mixture>
      <name>Kit for the preparation of Lymphoseek (technetium Tc 99m tilmanocept)</name>
      <ingredients>Technetium Tc-99m tilmanocept</ingredients>
    </mixture>
  </mixtures>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Diagnostic Radiopharmaceuticals</category>
      <mesh-id/>
    </category>
    <category>
      <category>Radioactive Diagnostic Agent</category>
      <mesh-id/>
    </category>
    <category>
      <category>Radiopharmaceutical Activity</category>
      <mesh-id/>
    </category>
    <category>
      <category>Technetium (99Mtc) Compounds</category>
      <mesh-id/>
    </category>
    <category>
      <category>Tumour Detection</category>
      <mesh-id/>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Kit</form>
      <route>Intradermal; Subcutaneous</route>
      <strength>250 ug/1</strength>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="V09IA09">
      <level code="V09IA">Technetium (99mTc) compounds</level>
      <level code="V09I">TUMOUR DETECTION</level>
      <level code="V09">DIAGNOSTIC RADIOPHARMACEUTICALS</level>
      <level code="V">VARIOUS</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes/>
  <pdb-entries/>
  <fda-label>//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB09266.pdf?1516048816</fda-label>
  <msds>//s3-us-west-2.amazonaws.com/drugbank/msds/DB09266.pdf?1516048816</msds>
  <patents>
    <patent>
      <number>6409990</number>
      <country>United States</country>
      <approved>2002-06-25</approved>
      <expires>2020-05-12</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>9439985</number>
      <country>United States</country>
      <approved>2016-09-13</approved>
      <expires>2033-09-27</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
  </patents>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB00281</drugbank-id>
      <name>Lidocaine</name>
      <description>Lidocaine may decrease effectiveness of Technetium Tc-99m tilmanocept as a diagnostic agent.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00296</drugbank-id>
      <name>Ropivacaine</name>
      <description>Ropivacaine may decrease effectiveness of Technetium Tc-99m tilmanocept as a diagnostic agent.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00297</drugbank-id>
      <name>Bupivacaine</name>
      <description>Bupivacaine may decrease effectiveness of Technetium Tc-99m tilmanocept as a diagnostic agent.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00527</drugbank-id>
      <name>Cinchocaine</name>
      <description>Cinchocaine may decrease effectiveness of Technetium Tc-99m tilmanocept as a diagnostic agent.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00645</drugbank-id>
      <name>Dyclonine</name>
      <description>Dyclonine may decrease effectiveness of Technetium Tc-99m tilmanocept as a diagnostic agent.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00721</drugbank-id>
      <name>Procaine</name>
      <description>Procaine may decrease effectiveness of Technetium Tc-99m tilmanocept as a diagnostic agent.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00750</drugbank-id>
      <name>Prilocaine</name>
      <description>Prilocaine may decrease effectiveness of Technetium Tc-99m tilmanocept as a diagnostic agent.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00907</drugbank-id>
      <name>Cocaine</name>
      <description>Cocaine may decrease effectiveness of Technetium Tc-99m tilmanocept as a diagnostic agent.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00961</drugbank-id>
      <name>Mepivacaine</name>
      <description>Mepivacaine may decrease effectiveness of Technetium Tc-99m tilmanocept as a diagnostic agent.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01002</drugbank-id>
      <name>Levobupivacaine</name>
      <description>Levobupivacaine may decrease effectiveness of Technetium Tc-99m tilmanocept as a diagnostic agent.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01075</drugbank-id>
      <name>Diphenhydramine</name>
      <description>Diphenhydramine may decrease effectiveness of Technetium Tc-99m tilmanocept as a diagnostic agent.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01086</drugbank-id>
      <name>Benzocaine</name>
      <description>Benzocaine may decrease effectiveness of Technetium Tc-99m tilmanocept as a diagnostic agent.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01161</drugbank-id>
      <name>Chloroprocaine</name>
      <description>Chloroprocaine may decrease effectiveness of Technetium Tc-99m tilmanocept as a diagnostic agent.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03255</drugbank-id>
      <name>Phenol</name>
      <description>Phenol may decrease effectiveness of Technetium Tc-99m tilmanocept as a diagnostic agent.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05232</drugbank-id>
      <name>Tetrodotoxin</name>
      <description>Tetrodotoxin may decrease effectiveness of Technetium Tc-99m tilmanocept as a diagnostic agent.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06770</drugbank-id>
      <name>Benzyl alcohol</name>
      <description>Benzyl alcohol may decrease effectiveness of Technetium Tc-99m tilmanocept as a diagnostic agent.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06774</drugbank-id>
      <name>Capsaicin</name>
      <description>Capsaicin may decrease effectiveness of Technetium Tc-99m tilmanocept as a diagnostic agent.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08987</drugbank-id>
      <name>Etidocaine</name>
      <description>Etidocaine may decrease effectiveness of Technetium Tc-99m tilmanocept as a diagnostic agent.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09009</drugbank-id>
      <name>Articaine</name>
      <description>Articaine may decrease effectiveness of Technetium Tc-99m tilmanocept as a diagnostic agent.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09085</drugbank-id>
      <name>Tetracaine</name>
      <description>Tetracaine may decrease effectiveness of Technetium Tc-99m tilmanocept as a diagnostic agent.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09342</drugbank-id>
      <name>Propoxycaine</name>
      <description>Propoxycaine may decrease effectiveness of Technetium Tc-99m tilmanocept as a diagnostic agent.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09345</drugbank-id>
      <name>Pramocaine</name>
      <description>Pramocaine may decrease effectiveness of Technetium Tc-99m tilmanocept as a diagnostic agent.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11502</drugbank-id>
      <name>Butacaine</name>
      <description>Butacaine may decrease effectiveness of Technetium Tc-99m tilmanocept as a diagnostic agent.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12532</drugbank-id>
      <name>Oxetacaine</name>
      <description>Oxetacaine may decrease effectiveness of Technetium Tc-99m tilmanocept as a diagnostic agent.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13328</drugbank-id>
      <name>Butanilicaine</name>
      <description>Butanilicaine may decrease effectiveness of Technetium Tc-99m tilmanocept as a diagnostic agent.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13578</drugbank-id>
      <name>Metabutethamine</name>
      <description>Metabutethamine may decrease effectiveness of Technetium Tc-99m tilmanocept as a diagnostic agent.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13683</drugbank-id>
      <name>Quinisocaine</name>
      <description>Quinisocaine may decrease effectiveness of Technetium Tc-99m tilmanocept as a diagnostic agent.</description>
    </drug-interaction>
  </drug-interactions>
  <calculated-properties/>
  <experimental-properties>
    <property>
      <kind>Boiling Point</kind>
      <value>100</value>
      <source>MSDS</source>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>347910428</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target position="1">
      <id>BE0009334</id>
      <name>Macrophage mannose receptor 1</name>
      <organism>Humans</organism>
      <actions>
        <action>ligand</action>
      </actions>
      <references>
        <articles/>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P22897" source="Swiss-Prot">
        <name>Macrophage mannose receptor 1</name>
        <general-function>Mediates the endocytosis of glycoproteins by macrophages. Binds both sulfated and non-sulfated polysaccharide chains.</general-function>
        <specific-function>Mannose binding</specific-function>
        <gene-name>MRC1</gene-name>
        <locus>10p12.33</locus>
        <cellular-location>Endosome membrane</cellular-location>
        <transmembrane-regions>1390-1410</transmembrane-regions>
        <signal-regions>1-18</signal-regions>
        <theoretical-pi/>
        <molecular-weight>166010.315</molecular-weight>
        <chromosome-location>10</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:7228</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P22897</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>MRC1_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>C-type lectin domain family 13 member D</synonym>
          <synonym>C-type lectin domain family 13 member D-like</synonym>
          <synonym>CLEC13D</synonym>
          <synonym>CLEC13DL</synonym>
          <synonym>hMR</synonym>
          <synonym>Human mannose receptor</synonym>
          <synonym>Macrophage mannose receptor 1-like protein 1</synonym>
          <synonym>MMR</synonym>
          <synonym>MRC1L1</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0051590|Macrophage mannose receptor 1
MRLPLLLVFASVIPGAVLLLDTRQFLIYNEDHKRCVDAVSPSAVQTAACNQDAESQKFRW
VSESQIMSVAFKLCLGVPSKTDWVAITLYACDSKSEFQKWECKNDTLLGIKGEDLFFNYG
NRQEKNIMLYKGSGLWSRWKIYGTTDNLCSRGYEAMYTLLGNANGATCAFPFKFENKWYA
DCTSAGRSDGWLWCGTTTDYDTDKLFGYCPLKFEGSESLWNKDPLTSVSYQINSKSALTW
HQARKSCQQQNAELLSITEIHEQTYLTGLTSSLTSGLWIGLNSLSFNSGWQWSDRSPFRY
LNWLPGSPSAEPGKSCVSLNPGKNAKWENLECVQKLGYICKKGNTTLNSFVIPSESDVPT
HCPSQWWPYAGHCYKIHRDEKKIQRDALTTCRKEGGDLTSIHTIEELDFIISQLGYEPND
ELWIGLNDIKIQMYFEWSDGTPVTFTKWLRGEPSHENNRQEDCVVMKGKDGYWADRGCEW
PLGYICKMKSRSQGPEIVEVEKGCRKGWKKHHFYCYMIGHTLSTFAEANQTCNNENAYLT
TIEDRYEQAFLTSFVGLRPEKYFWTGLSDIQTKGTFQWTIEEEVRFTHWNSDMPGRKPGC
VAMRTGIAGGLWDVLKCDEKAKFVCKHWAEGVTHPPKPTTTPEPKCPEDWGASSRTSLCF
KLYAKGKHEKKTWFESRDFCRALGGDLASINNKEEQQTIWRLITASGSYHKLFWLGLTYG
SPSEGFTWSDGSPVSYENWAYGEPNNYQNVEYCGELKGDPTMSWNDINCEHLNNWICQIQ
KGQTPKPEPTPAPQDNPPVTEDGWVIYKDYQYYFSKEKETMDNARAFCKRNFGDLVSIQS
ESEKKFLWKYVNRNDAQSAYFIGLLISLDKKFAWMDGSKVDYVSWATGEPNFANEDENCV
TMYSNSGFWNDINCGYPNAFICQRHNSSINATTVMPTMPSVPSGCKEGWNFYSNKCFKIF
GFMEEERKNWQEARKACIGFGGNLVSIQNEKEQAFLTYHMKDSTFSAWTGLNDVNSEHTF
LWTDGRGVHYTNWGKGYPGGRRSSLSYEDADCVVIIGGASNEAGKWMDDTCDSKRGYICQ
TRSDPSLTNPPATIQTDGFVKYGKSSYSLMRQKFQWHEAETYCKLHNSLIASILDPYSNA
FAWLQMETSNERVWIALNSNLTDNQYTWTDKWRVRYTNWAADEPKLKSACVYLDLDGYWK
TAHCNESFYFLCKRSDEIPATEPPQLPGRCPESDHTAWIPFHGHCYYIESSYTRNWGQAS
LECLRMGSSLVSIESAAESSFLSYRVEPLKSKTNFWIGLFRNVEGTWLWINNSPVSFVNW
NTGDPSGERNDCVALHASSGFWSNIHCSSYKGYICKRPKIIDAKPTHELLTTKADTRKMD
PSKPSSNVAGVVIIVILLILTGAGLAAYFFYKKRRVHLPQEGAFENTLYFNSQSSPGTSD
MKDLVGNIEQNEHSVI</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0051591|Macrophage mannose receptor 1 (MRC1)
ATGAGGCTACCCCTGCTCCTGGTTTTTGCCTCTGTCATTCCGGGTGCTGTTCTCCTACTG
GACACCAGGCAATTTTTAATCTATAATGAAGATCACAAGCGCTGCGTGGATGCAGTGAGT
CCCAGTGCCGTCCAAACCGCAGCTTGCAACCAGGATGCCGAATCACAGAAATTCCGATGG
GTGTCCGAATCTCAGATTATGAGTGTTGCATTTAAATTATGCCTGGGAGTGCCATCAAAA
ACGGACTGGGTTGCTATCACTCTCTATGCCTGTGACTCAAAAAGTGAATTTCAGAAATGG
GAGTGCAAAAATGACACACTTTTGGGGATCAAAGGAGAAGATTTATTTTTTAACTACGGC
AACAGACAAGAAAAGAATATTATGCTCTACAAGGGATCGGGTTTATGGAGCAGGTGGAAG
ATCTATGGAACCACAGACAATCTGTGCTCCAGAGGTTATGAAGCCATGTATACGCTACTA
GGCAATGCCAATGGAGCAACCTGTGCATTCCCGTTCAAGTTTGAAAACAAGTGGTACGCA
GATTGCACGAGTGCTGGGCGGTCGGATGGATGGCTCTGGTGCGGAACCACTACTGACTAT
GACACAGACAAGCTATTTGGATATTGTCCATTGAAATTTGAGGGCAGTGAAAGCTTATGG
AATAAAGACCCGCTGACCAGCGTTTCCTACCAGATAAACTCCAAATCCGCTTTAACGTGG
CACCAGGCGAGGAAAAGCTGCCAACAACAGAACGCTGAGCTCCTGAGCATCACAGAGATT
CATGAGCAAACATACCTGACAGGATTAACCAGTTCCTTGACCTCAGGACTCTGGATTGGA
CTTAACAGTCTGAGCTTCAACAGCGGTTGGCAGTGGAGTGACCGCAGTCCTTTCCGATAT
TTGAACTGGTTACCAGGAAGTCCATCAGCTGAACCTGGAAAAAGCTGTGTGTCACTAAAT
CCTGGAAAAAATGCTAAATGGGAAAATCTGGAATGTGTTCAGAAACTGGGCTATATTTGC
AAAAAGGGCAACACCACTTTAAATTCTTTTGTTATTCCCTCAGAAAGTGATGTGCCTACT
CACTGTCCTAGTCAGTGGTGGCCGTATGCCGGTCACTGTTACAAGATTCACAGAGATGAG
AAAAAAATCCAGAGGGATGCTCTGACCACCTGCAGGAAGGAAGGCGGTGACCTCACAAGT
ATCCACACCATCGAGGAATTGGACTTTATTATCTCCCAGCTAGGATATGAGCCAAATGAC
GAATTGTGGATCGGCTTAAATGACATTAAGATTCAAATGTACTTTGAGTGGAGTGATGGG
ACCCCTGTAACGTTTACCAAATGGCTTCGTGGAGAACCAAGCCATGAAAACAACAGACAG
GAGGATTGTGTGGTGATGAAAGGCAAGGATGGGTACTGGGCAGATCGGGGCTGTGAGTGG
CCTCTTGGCTACATCTGCAAGATGAAATCACGAAGCCAAGGTCCAGAAATAGTGGAAGTC
GAAAAAGGCTGCAGGAAAGGCTGGAAAAAACATCACTTTTACTGCTATATGATTGGACAT
ACGCTTTCAACATTTGCAGAAGCAAACCAAACCTGTAATAATGAGAATGCTTATTTAACA
ACTATTGAAGACAGATATGAACAAGCCTTCCTGACTAGTTTCGTTGGCTTAAGGCCTGAA
AAATATTTCTGGACAGGACTTTCAGATATACAAACCAAAGGGACTTTTCAGTGGACCATC
GAGGAAGAGGTTCGGTTCACCCACTGGAATTCAGATATGCCAGGGCGAAAGCCAGGGTGT
GTTGCCATGAGAACCGGGATTGCAGGGGGCTTATGGGATGTTTTGAAATGTGATGAAAAG
GCAAAATTTGTGTGCAAGCACTGGGCAGAAGGAGTAACCCACCCACCGAAGCCCACGACG
ACTCCCGAACCCAAATGTCCGGAGGATTGGGGCGCCAGCAGTAGAACAAGCTTGTGTTTC
AAGCTGTATGCAAAAGGAAAACATGAGAAGAAAACGTGGTTTGAATCTCGAGATTTTTGT
CGAGCTCTGGGTGGAGACTTAGCTAGCATCAATAACAAAGAGGAACAGCAAACAATATGG
CGATTAATAACAGCTAGTGGAAGCTACCACAAACTGTTTTGGTTGGGATTGACATATGGA
AGCCCTTCAGAAGGTTTTACTTGGAGTGATGGTTCTCCTGTTTCATATGAAAACTGGGCT
TATGGAGAACCTAATAATTATCAAAATGTTGAATACTGTGGTGAGCTGAAAGGTGACCCT
ACTATGTCTTGGAATGATATTAATTGTGAACACCTTAACAACTGGATTTGCCAGATACAA
AAAGGACAAACACCAAAACCTGAGCCAACACCAGCTCCTCAAGACAATCCACCAGTTACT
GAAGATGGGTGGGTTATTTACAAAGACTACCAGTATTATTTCAGCAAAGAGAAGGAAACC
ATGGACAATGCGCGAGCGTTTTGCAAGAGGAATTTTGGTGATCTTGTTTCTATTCAAAGT
GAAAGTGAAAAGAAGTTTCTATGGAAATATGTAAACAGAAATGATGCACAGTCTGCATAT
TTTATTGGTTTATTGATCAGCTTGGATAAAAAGTTTGCTTGGATGGATGGAAGCAAAGTG
GATTACGTGTCTTGGGCCACAGGTGAACCCAATTTTGCAAATGAAGATGAAAACTGTGTG
ACCATGTATTCAAATTCAGGGTTTTGGAATGACATTAACTGTGGCTATCCAAACGCCTTC
ATTTGCCAGCGACATAACAGTAGTATCAATGCTACCACAGTTATGCCTACCATGCCCTCG
GTCCCATCAGGGTGCAAGGAAGGTTGGAATTTCTACAGCAACAAGTGTTTCAAAATCTTT
GGATTTATGGAAGAAGAAAGAAAAAATTGGCAAGAGGCACGAAAAGCTTGTATAGGCTTT
GGAGGGAATCTGGTCTCCATACAAAATGAAAAAGAGCAAGCATTTCTTACCTATCACATG
AAGGACTCCACTTTCAGTGCCTGGACTGGGCTGAATGATGTCAATTCAGAACACACGTTC
CTTTGGACGGATGGACGAGGAGTCCATTACACAAACTGGGGGAAAGGTTACCCTGGTGGA
AGAAGAAGCAGTCTTTCTTATGAAGATGCTGACTGTGTTGTTATTATTGGAGGTGCATCA
AATGAAGCAGGAAAATGGATGGATGATACCTGCGACAGTAAACGAGGCTACATATGCCAG
ACACGATCCGACCCTTCCTTGACTAATCCTCCAGCAACGATTCAAACAGATGGCTTTGTT
AAATATGGCAAAAGCAGCTATTCACTCATGAGACAAAAATTTCAATGGCATGAAGCGGAG
ACATACTGCAAGCTTCACAATTCCCTTATAGCCAGCATTCTGGATCCCTACAGTAATGCA
TTTGCGTGGCTGCAGATGGAAACATCTAATGAACGTGTGTGGATCGCCCTGAACAGTAAC
TTGACTGATAATCAATACACTTGGACTGATAAGTGGAGGGTGAGGTACACTAACTGGGCT
GCTGATGAGCCCAAATTGAAATCAGCATGTGTTTATCTGGATCTTGATGGCTACTGGAAG
ACAGCACATTGCAATGAAAGTTTTTACTTTCTCTGTAAAAGATCAGATGAAATCCCTGCT
ACTGAACCCCCACAACTGCCTGGCAGATGCCCGGAGTCAGATCACACAGCATGGATTCCT
TTCCATGGTCACTGTTACTATATTGAGTCCTCATATACAAGAAACTGGGGCCAAGCTTCT
CTGGAATGTCTTCGAATGGGTTCCTCTCTGGTTTCCATTGAAAGTGCTGCAGAATCCAGT
TTTCTGTCATATCGGGTTGAGCCACTTAAAAGTAAAACCAATTTTTGGATAGGATTGTTC
AGAAATGTTGAAGGGACGTGGCTGTGGATAAATAACAGTCCGGTCTCCTTTGTCAACTGG
AACACAGGAGATCCCTCTGGTGAACGGAATGATTGTGTAGCTTTACATGCGTCTTCTGGG
TTTTGGAGTAATATTCACTGTTCATCCTACAAAGGATATATTTGTAAAAGACCAAAAATT
ATTGATGCTAAACCTACTCATGAATTACTTACAACAAAAGCTGACACAAGGAAGATGGAC
CCTTCTAAACCGTCTTCCAACGTGGCCGGAGTAGTCATCATTGTGATCCTCCTGATTTTA
ACGGGTGCTGGCCTTGCCGCCTATTTCTTTTATAAGAAAAGACGTGTGCACCTACCTCAA
GAGGGCGCCTTTGAAAACACTCTGTATTTTAACAGTCAGTCAAGCCCAGGAACTAGTGAT
ATGAAAGATCTCGTGGGCAATATTGAACAGAATGAACACTCGGTCATCTAG</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00040</identifier>
            <name>fn2</name>
          </pfam>
          <pfam>
            <identifier>PF00059</identifier>
            <name>Lectin_C</name>
          </pfam>
          <pfam>
            <identifier>PF00652</identifier>
            <name>Ricin_B_lectin</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cell surface</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endosome membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>mannose binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>transmembrane signaling receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>virus receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to interferon-gamma</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to interleukin-4</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to lipopolysaccharide</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>receptor-mediated endocytosis</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>